Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MTVA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMetaVia reports 9.1% weight loss in Phase 1 obesity trial for DA-1726, advances pipeline
Filed June 8, 2026 · Period ending June 8, 2026 · ~1 min read
Key Changes
-
high
DA-1726 achieved 9.1% weight loss at Day 54 in Phase 1 trial with no serious adverse events or treatment discontinuations, showing continued reduction through Week 8 without plateau—supporting advancement to later-stage obesity studies.
Item 7.01: Phase 1 Results verify on EDGAR → -
high
Phase 1 data showed DA-1726 was well-tolerated with mild-to-moderate GI side effects, dose-proportional pharmacokinetics, and statistically significant reductions in waist circumference (9.8 cm) and BMI (3.4 kg/m²) at Day 54.
Item 7.01: Safety & Efficacy verify on EDGAR → -
medium
Preclinical data for vanoglipel combined with resmetirom showed 23.6% weight reduction and 83.5% ALT reduction in MASH models, where neither drug alone affected weight—first demonstration of GPR119 plus thyroid hormone receptor beta targeting.
Item 7.01: Combination Data verify on EDGAR → -
medium
Vanoglipel plus metformin combination achieved 16.3% weight reduction versus 4% for monotherapies in preclinical studies, with 6.4-fold increase in GLP-1 levels suggesting enhanced gut hormone activity for metabolic disease treatment.
Item 7.01: Metformin Combo verify on EDGAR →
Summary
MetaVia disclosed positive Phase 1 clinical data for its lead obesity drug candidate DA-1726 at the American Diabetes Association's 2026 Scientific Sessions. The dual GLP-1/glucagon receptor agonist produced statistically significant weight loss of 9.1% at Day 54 in obese adults, with continued reduction through Week 8 and no evidence of plateau.
Importantly, the drug was well-tolerated with no serious adverse events or treatment discontinuations, addressing a key concern for obesity therapeutics. The data support advancing DA-1726 into later-stage trials in a competitive but lucrative obesity market.
The company also presented preclinical combination therapy data for vanoglipel (DA-1241), a GPR119 agonist, showing synergistic effects when paired with either resmetirom for MASH or metformin for diabetes. These combinations produced weight and metabolic improvements neither drug achieved alone, potentially opening differentiated treatment approaches. For retail investors, the key near-term catalyst is whether MetaVia announces Phase 2 trial initiation for DA-1726 and secures partnership interest given the competitive obesity drug landscape. Watch for any guidance on trial timelines or manufacturing scale-up in upcoming earnings calls.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
MetaVia announced new Phase 1 data for obesity drug DA-1726 and preclinical data for vanoglipel at ADA 2026 Scientific Sessions.
Added in current filing · verify on EDGAR →
The presentations included new Phase 1 higher-dose cohort results for DA-1726, a novel dual agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR)
MetaVia disclosed new Phase 1 clinical trial results for DA-1726, a dual-agonist drug candidate for obesity and metabolic disease, at the American Diabetes Association's 2026 Scientific Sessions. The data covered higher-dose cohorts, representing progression in the drug's development program.
Added in current filing · verify on EDGAR →
preclinical data supporting combination treatment potential for vanoglipel (DA-1241), a novel G-protein-coupled receptor 119 (GPR119) agonist, in metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2D) and obesity
MetaVia presented preclinical data for vanoglipel (DA-1241), a GPR119 agonist, showing potential for combination therapy in MASH, type 2 diabetes, and obesity. This expands the company's pipeline strategy beyond single-agent approaches to combination treatments for metabolic diseases.
Event · Item 8.01 — Other Events
MetaVia presented positive Phase 1 obesity trial data for DA-1726 and preclinical combination studies for vanoglipel at ADA 2026.
Added in current filing · verify on EDGAR →
In the 48 mg cohort, DA-1726 was generally well tolerated, with predominantly mild-to-moderate and transient gastrointestinal adverse events and no treatment-related discontinuations or serious adverse events. Pharmacokinetic (PK) analysis demonstrated sustained exposure with dose-proportional behavior. DA-1726 produced a 6.1% reduction in body weight at Day 26 and a 9.1% reduction at Day 54 (p<0.05 vs placebo at Day 26), with continued reductions through Week 8 and no evidence of plateau. Waist circumference was reduced by 5.8 cm at Day 22 and 9.8 cm at Day 54 (p<0.05 vs placebo), with accompanying reductions in BMI of 2.3 kg/m² and 3.4 kg/m² at Day 22 and Day 54, respectively.
MetaVia disclosed interim Phase 1 results showing DA-1726 achieved statistically significant weight loss of 9.1% at Day 54 in obese adults, with good tolerability and no serious adverse events. The drug showed dose-proportional pharmacokinetics and continued weight reduction through Week 8 without plateauing, supporting advancement to later-stage obesity trials.
Event · Item 9.01 — Financial Statements and Exhibits
MetaVia filed an 8-K attaching a press release dated June 8, 2026; no material event details disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
Exhibit | Number | Exhibit Description | 99.1 | Press Release dated June 8, 2026.
The 8-K lists a press release dated June 8, 2026 as Exhibit 99.1. The filing body provides no details about the content or subject matter of the press release, so the nature of the disclosed event cannot be determined from this 8-K alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify